For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Xention Limited

USPTO Granted Patents = 22

EPO Patents = 6

Forward Citations = 122

Loading Chart...

Loading Chart...

47 inventors (with patents filed for the assignee):

David John Madge (12 out of 14 patents)

Derek Edward John (10 out of 11 patents)

John Ford (10 out of 11 patents)

4. Basil Hartzoulakis (7 out of 11 patents)

5. Muneto Mogi (6 out of 32 patents)

6. Mushtaq Mulla (6 out of 7 patents)

7. Richard John Hamlyn (6 out of 7 patents)

8. Klaus Urbahns (6 out of 24 patents)

9. Masaomi Tajimi (6 out of 11 patents)

10. Yasuhiro Tsukimi (6 out of 7 patents)

11. Takeshi Yura (6 out of 8 patents)

12. Noriyuki Yamamoto (6 out of 9 patents)

13. Hiroshi Fujishima (6 out of 8 patents)

14. Toshiya Moriwaki (5 out of 12 patents)

15. Toshio Kokubo (5 out of 6 patents)

22 patents: Sort by Forward Citations

1. 9290511 - Thieno-pyrimidines, useful as potassium channel inhibitors (2016-03-22),

2. 9249155 - Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia (2016-02-02),

3. 9216992 - Thieno[3,2-c]pyridine potassium channel inhibitors (2015-12-22),

4. 9073834 - Potassium channel blockers (2015-07-07),

5. 8759017 - High throughput screen (2014-06-24),

6. 8673901 - Potassium channel blockers (2014-03-18),

7. 8449825 - High throughput screen (2013-05-28),

8. 8426442 - Compounds (2013-04-23),

9. 8399481 - Compounds (2013-03-19),

10. 8372840 - Potassium channel blockers (2013-02-12),

11. 8258138 - Potassium channel blockers (2012-09-04),

12. 8193215 - Thieno[2 3-b]pyridines as potassium channel inhibitors (2012-06-05),

13. 8173841 - Tetrahydro-naphthalene derivatives (2012-05-08),

14. 8088826 - Tetrahydro-naphthalene derivatives (2012-01-03),

15. 8022076 - Substituted thieno[2,3-d]pyrimidines as potassium channel inhibitors (2011-09-20),

Xention Limited is a biopharmaceutical company specializing in the research and development of innovative ion channel-modulating medicines. With a focus on cardiovascular, metabolic, and neurological diseases, Xention aims to enhance patient outcomes through the discovery of novel treatments. Their deep expertise in ion channel biology and drug discovery enables the development of therapeutic solutions for unmet medical needs. Xention is committed to making a positive impact on patient care and improving the quality of life for individuals suffering from various conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

22 Patents

#45 in Cambridge

#804 in United Kingdom

#27,908 in the World

Cambridge, United Kingdom

Xention Limited

Forward Citations = 122

47 inventors:

David John Madge (12 out of 14 patents)

Derek Edward John (10 out of 11 patents)

John Ford (10 out of 11 patents)

4. Basil Hartzoulakis (7 out of 11 patents)

5. Muneto Mogi (6 out of 32 patents)

Please report any incorrect information to support@idiyas.com

Loading…